Advertisement

AIDS and Behavior

, Volume 22, Issue 4, pp 1383–1394 | Cite as

Continued Transmission of HIV Among Young Adults Who Inject Drugs in San Francisco: Still Room for Improvement

  • Ali Mirzazadeh
  • Jennifer L. Evans
  • Judith A. Hahn
  • Jennifer Jain
  • Alya Briceno
  • Stephen Shiboski
  • Paula J. Lum
  • Christopher Bentsen
  • Geoff Davis
  • Kathy Shriver
  • Melanie Dimapasoc
  • Mars Stone
  • Michael P. Busch
  • Kimberly Page
Original Paper

Abstract

We measured HIV incidence rate, trend and risk factors in 564 HIV-negative young people (< 30 years) who inject drugs (PWID) in San Francisco between 2000 and 2014. HIV incidence was 0.93/100 person-years (PY; 95% CI 0.50, 1.73). Incidence varied between 0.62/100 PY in 2000–2002 and 1.06/100 PY in 2012–2014 (P for trend = 1.0). HIV incidence varied significantly (P < 0.01) by race/ethnicity: among Hispanics it was 8.19/100 PY (95% CI 3.41, 19.68), African-Americans 4.59/100 PY (95% CI 1.15, 18.37), and Whites 0.26/100 PY (95% CI 0.06, 1.03). Male participants who reported sex with men (MSM) had higher HIV incidence (2.63/100 PY; 95% CI 1.31, 5.25) compared to males who did not report MSM (0.50/100 PY; 95% CI 0.12, 1.99) (P = 0.01). Despite an overall stable HIV incidence trend, incidence was elevated among African-American and Hispanic PWID, and men who have sex with men. Addressing prevention needs in these key populations is critical for the goal of eliminating HIV transmission.

Keywords

HIV Incidence Epidemiology Drug users Injection Young adults Cohort studies San Francisco 

Resumen

Medimos la tasa de incidencia y factores de tendencia y de riesgo del VIH en 564 jóvenes (menores de 30 años) VIH-negativos que se inyectan drogas en San Francisco entre el 2000 y el 2014. La incidencia de VIH fue de 0.93/100 personas-años (IC 95%: 0.50, 1.73). La incidencia varió entre 0.62/100 personas-años entre el 2000 y el 2002 y 1.06/100 personas-años entre el 2012 y el 2014 (P de tendencia = 1.0). La incidencia del VIH varió significativamente (p < 0.001) por raza/etnicidad: entre Hispanos fue de 8.19/100 personas-años (IC 95%: 3.41, 19.68), Afroamericanos 4.59/100 personas-años (IC 95%: 1.15, 18.37), y Blancos 0.26/100 personas-años (IC 95%: 0.06, 1.03). Los participantes masculinos que reportaron sexo con hombres tuvieron la mayor incidencia de VIH (2.63/100 personas-años; IC 95%: 1.31, 5.25) en comparación con participantes masculinos que no reportaron sexo con hombres (0.50/100 personas-años; IC 95%: 0.12, 1.99) (P = 0.01). A pesar de una tendencia de incidencia de VIH universalmente estable, la incidencia fue elevada entre personas (que se inyectan) Afroamericanas e Hispanas, y entre hombres que tienen sexo con hombres. Dirigir necesidades de prevención en estas poblaciones clave es vital para la meta de eliminar la transmisión del VIH.

Notes

Acknowledgements

The authors thank Dr. Meghan Morris for her contributions to this study. We also recognize the important contribution of San Francisco Department of Public Health, Berkeley Free Clinic, Homeless Youth Alliance, San Francisco Community Clinic Consortium Street Outreach Services, and San Francisco AIDS Foundation. This paper is dedicated to the memory of Joep Lange, whose brilliance and passion to HIV prevention will be forever missed.

Funding

This study was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number R01DA016017 (KP), NIHK24 under Award Number AA022586 (JAH) and NIMH R25 under Award Number MH064712 (AM). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

10461_2017_1988_MOESM1_ESM.docx (126 kb)
Supplementary material 1 (DOCX 127 kb)

References

  1. 1.
    Centers for Disease Control and Prevention. HIV Surveillance Report, 2014; vol. 26. http://www.cdc.gov/hiv/library/reports/surveillance/. Published November 2015. Accessed 15 July 2016.
  2. 2.
    Coffin PO, Jin H, Huriaux E, Mirzazadeh A, Raymond HF. Trends in use of health care and HIV prevention services for persons who inject drugs in San Francisco: Results from national HIV behavioral surveillance 2005–2012. Drug Alcohol Depend. 2015;146:45–51.CrossRefPubMedGoogle Scholar
  3. 3.
    Bluthenthal RN, Kral AH, Lorvick J, Erringer EA, Edlin BR. Harm reduction and needle exchange programmes. Lancet. 1998;351(9118):1819–20.CrossRefPubMedGoogle Scholar
  4. 4.
    Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology. 2001;34(1):180–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Lutnick A, Cooper E, Dodson C, Bluthenthal R, Kral AH. Pharmacy syringe purchase test of nonprescription syringe sales in San Francisco and Los Angeles in 2010. J Urban Health. 2013;90(2):276–83.CrossRefPubMedGoogle Scholar
  6. 6.
    Jaffe JH, O’Keeffe C. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend. 2003;70(2 Suppl):S3–11.CrossRefPubMedGoogle Scholar
  7. 7.
    Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med. 2014;174(12):1974–81.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Colfax GN, Santos GM, Das M, et al. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatry. 2011;68(11):1168–75.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    City and County of San Francisco DoPH. http://www.sfhiv.org/our-services. Accessed 10 March 2015.
  10. 10.
    Des Jarlais DC, Kerr T, Carrieri P, Feelemyer J, Arasteh K. HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks. AIDS. 2016;30(6):815–26.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    San Francisco Department of Public Health—HIV epidemiology section. HIV epidemiology annual report 2014 (https://www.sfdph.org/dph/files/reports/RptsHIVAIDS/HIV-EpidemiologyAnnualReport-2014.pdf). 2015.
  12. 12.
    Conrad C, Bradley HM, Broz D, et al. Community outbreak of HIV Infection linked to injection drug use of oxymorphone-Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(16):443–4.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Valdiserri R, Khalsa J, Dan C, et al. Confronting the emerging epidemic of HCV infection among young injection drug users. Am J Public Health. 2014;104(5):816–21.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    U.S. Department of Health and Human Services (HHS) Office. Technical consultation on hepatitis C virus infection in young persons who inject drugs. http://aids.gov/pdf/hcv-and-young-pwid-consultation-report.pdf. 2013.
  15. 15.
    Suryaprasad AG, White JZ, Xu F, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Clin Infect Dis. 2014;59(10):1411–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Fraser H, Zibbell J, Hoerger T, et al. Scaling up HCV prevention and treatment interventions in rural USA—model projections for tackling an increasing epidemic. Addiction. 2017;.  https://doi.org/10.1111/add.13948.Google Scholar
  17. 17.
    Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol. 2008;168(10):1099–109.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Rondinelli AJ, Ouellet LJ, Strathdee SA, et al. Young adult injection drug users in the United States continue to practice HIV risk behaviors. Drug Alcohol Depend. 2009;104(1–2):167–74.CrossRefPubMedGoogle Scholar
  19. 19.
    Hahn JA, Page-Shafer K, Ford J, Paciorek A, Lum PJ. Traveling young injection drug users at high risk for acquisition and transmission of viral infections. Drug Alcohol Depend. 2008;93(1–2):43–50.CrossRefPubMedGoogle Scholar
  20. 20.
    Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis. 2009;200(8):1216–26.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Hahn JA, Page-Shafer K, Lum PJ, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis. 2002;186(11):1558–64.CrossRefPubMedGoogle Scholar
  22. 22.
    Evans JL, Tsui JI, Hahn JA, et al. Mortality among young injection drug users in San Francisco: a 10-year follow-up of the UFO study. Am J Epidemiol. 2012;175(4):302–8.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Des Jarlais DC, Bramson HA, Wong C, et al. Racial/ethnic disparities in HIV infection among people who inject drugs: an international systematic review and meta-analysis. Addiction. 2012;107(12):2087–95.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Broz D, Wejnert C, Pham HT, et al. HIV infection and risk, prevention, and testing behaviors among injecting drug users—national HIV behavioral surveillance system, 20 U.S. cities, 2009. MMWR Morb Mortal Wkly Rep. 2014;63(6):1–51.Google Scholar
  25. 25.
    Cuzick J. A Wilcoxon-type test for trend. Stat Med. 1985;4:87.CrossRefPubMedGoogle Scholar
  26. 26.
    Kleinbaum DG, Klein M. Survival analysis; a self-learning text. 3rd ed. New York: Springer; 2012.Google Scholar
  27. 27.
    Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6):656–64.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Hardnett FP, Pals SL, Borkowf CB, et al. Assessing mediation in HIV intervention studies. Public Health Rep. 2009;124(2):288–94.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    D’Agostino R, Lee M, Belanger A, et al. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham heart study. Stat Med. 1990;9:1501–15.CrossRefPubMedGoogle Scholar
  30. 30.
    Kral AH, Lorvick J, Martinez A, et al. HIV prevalence and risk among heterosexual methamphetamine injectors in California. Subst Use Misuse. 2011;46(9):1081–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Des Jarlais DC, Arasteh K, McKnight C, et al. HIV infection during limited versus combined HIV prevention programs for IDUs in New York City: the importance of transmission behaviors. Drug Alcohol Depend. 2010;109(1–3):154–60.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Kim NJ, Jin H, McFarland W, Raymond HF. Trends in sources and sharing of needles among people who inject drugs, San Francisco, 2005–2012. Int J Drug Policy. 2015;26:1238–43.CrossRefPubMedGoogle Scholar
  33. 33.
    Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011;204(1):74–83.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Hellard M, Rolls DA, Sacks-Davis R, et al. The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs. Hepatology. 2014;60(6):1861–70.CrossRefPubMedGoogle Scholar
  35. 35.
    Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.CrossRefPubMedGoogle Scholar
  36. 36.
    Lampejo T, Turner R, Roberts C, et al. Novel outreach settings to enhance sexually transmitted infection/HIV awareness, diagnosis and treatment in hard-to-reach populations. Int J STD AIDS. 2017;.  https://doi.org/10.1177/0956462417723816.Google Scholar
  37. 37.
    Des Jarlais DC, Diaz T, Perlis T, et al. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol. 2003;157(5):467–71.CrossRefPubMedGoogle Scholar
  38. 38.
    Garfein RS, Rondinelli A, Barnes RF, et al. HCV infection prevalence lower than expected among 18–40-year-old injection drug users in San Diego, CA. J Urban Health. 2013;90(3):516–28.CrossRefPubMedGoogle Scholar
  39. 39.
    Bruneau J, Daniel M, Abrahamowicz M, et al. Trends in human immunodeficiency virus incidence and risk behavior among injection drug users in montreal, Canada: a 16-year longitudinal study. Am J Epidemiol. 2011;173(9):1049–58.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Wood E, Kerr T, Marshall BD, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009;338:b1649.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Kim SG, Lowe EL, Dixit D, et al. Cocaine-mediated impact on HIV infection in humanized BLT mice. Sci Rep. 2015;5:10010.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Lansky A, Finlayson T, Johnson C, et al. Estimating the number of persons who inject drugs in the united states by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS ONE. 2014;9(5):e97596.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Des Jarlais DC, McCarty D, Vega WA, Bramson H. HIV infection among people who inject drugs: the challenge of racial/ethnic disparities. Am Psychol. 2013;68(4):274–85.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Centers for Disease Control and Prevention. HIV surveillance report, 2015; vol. 27. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published November 2016. Accessed 11 March 2017. 2016.
  45. 45.
    Passel J, Cohn DV, Hugo Lopez M. Hispanics account for more than half of nation’s growth in past decade. http://www.pewhispanic.org/2011/03/24/hispanics-account-for-more-than-half-of-nations-growth-in-past-decade. Accessed 11 March 2017.
  46. 46.
    Glasman LR, Weinhardt LS, Hackl KL. Disparities in access to HIV prevention among men of Mexican descent living in the Midwestern United States. J Immigr Minor Health. 2011;13(6):1125–33.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Neaigus A, Reilly KH, Jenness SM, et al. Multilevel risk factors for greater HIV infection of black men who have sex with men in New York City. Sex Transm Dis. 2014;41(7):433–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Arrington-Sanders R, Morgan A, Oidtman J, et al. A medical care missed opportunity: preexposure prophylaxis and young black men who have sex with men. J Adolesc Health. 2016;59(6):725–8.CrossRefPubMedGoogle Scholar
  49. 49.
    Rolle CP, Rosenberg ES, Siegler AJ, et al. Challenges in translating PrEP interest into uptake in an observational study of young black MSM. J Acquir Immune Defic Syndr. 2017;76(3):250–8.CrossRefPubMedGoogle Scholar
  50. 50.
    Minior T, Galea S, Stuber J, Ahern J, Ompad D. Racial differences in discrimination experiences and responses among minority substance users. Ethn Dis. 2003;13(4):521–7.PubMedGoogle Scholar
  51. 51.
    Cooper H, Friedman SR, Tempalski B, Friedman R, Keem M. Racial/ethnic disparities in injection drug use in large US metropolitan areas. Ann Epidemiol. 2005;15(5):326–34.CrossRefPubMedGoogle Scholar
  52. 52.
    Raymond HF, McFarland W. Racial mixing and HIV risk among men who have sex with men. AIDS Behav. 2009;13(4):630–7.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Vieira I, Cheng R, Harper P, de Senna V. Small world network models of the dynamics of HIV infection. Ann Oper Res. 2010;178(1):173–200.CrossRefGoogle Scholar
  54. 54.
    Little SJ, Kosakovsky Pond SL, Anderson CM, et al. Using HIV networks to inform real time prevention interventions. PLoS ONE. 2014;9(6):e98443.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Shafer KP, Hahn JA, Lum PJ, et al. Prevalence and correlates of HIV infection among young injection drug users in San Francisco. J Acquir Immune Defic Syndr. 2002;31(4):422–31.CrossRefPubMedGoogle Scholar
  56. 56.
    Bacon O, Lum P, Hahn J, et al. Commercial sex work and risk of HIV infection among young drug-injecting men who have sex with men in San Francisco. Sex Transm Dis. 2006;33(4):228–34.CrossRefPubMedGoogle Scholar
  57. 57.
    Jin H, Huriaux E, Loughran E, Packer T, Raymond HF. Differences in HIV risk behaviors among people who inject drugs by gender and sexual orientation, San Francisco, 2012. Drug Alcohol Depend. 2014;145:180–4.CrossRefPubMedGoogle Scholar
  58. 58.
    Rosario M, Schrimshaw EW, Hunter J. Disclosure of sexual orientation and subsequent substance use and abuse among lesbian, gay, and bisexual youths: critical role of disclosure reactions. Psychol Addict Behav. 2009;23(1):175–84.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Vittinghoff E, Glidden DV, Shiboski SC, McCulloch CE. Regression methods in biostatistics. New York: Springer; 2012.CrossRefGoogle Scholar
  60. 60.
    Sordo L, Bravo MJ, Barrio G, et al. Potential bias due to outcome-related loss to follow-up in cohort studies on incidence of drug injection: systematic review and meta-analysis. Addiction. 2015;110(8):1247–57.CrossRefPubMedGoogle Scholar
  61. 61.
    Maher L, Page K, et al. Commentary on Sordo et al. (2015): Reducing bias in prospective observational studies of drug users: The need for upstream and downstream approaches. Addiction. 2015;110(8):1259–61.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Des Jarlais DC, Arasteh K, Friedman SR. HIV among drug users at Beth Israel Medical Center, New York City, the first 25 years. Subst Use Misuse. 2011;46(2–3):131–9.CrossRefPubMedGoogle Scholar
  63. 63.
    Escudero DJ, Lurie MN, Kerr T, Howe CJ, Marshall BD. HIV pre-exposure prophylaxis for people who inject drugs: a review of current results and an agenda for future research. J Int AIDS Soc. 2014;17:1–5.CrossRefGoogle Scholar
  64. 64.
    San Francisco Department of Public Health HIV Prevention Section. 2010 San Francisco HIV Prevention Plan—Chapter 4: Strategies & Interventions. San Francisco; 2010.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2017

Authors and Affiliations

  • Ali Mirzazadeh
    • 1
  • Jennifer L. Evans
    • 1
  • Judith A. Hahn
    • 1
    • 2
  • Jennifer Jain
    • 3
  • Alya Briceno
    • 1
  • Stephen Shiboski
    • 4
  • Paula J. Lum
    • 2
  • Christopher Bentsen
    • 5
  • Geoff Davis
    • 5
  • Kathy Shriver
    • 5
  • Melanie Dimapasoc
    • 6
  • Mars Stone
    • 6
  • Michael P. Busch
    • 6
    • 7
  • Kimberly Page
    • 8
  1. 1.Department of Epidemiology and Biostatistics, Institute for Global Health SciencesUniversity of California, San FranciscoSan FranciscoUSA
  2. 2.Department of Medicine, San Francisco General HospitalUniversity of California, San FranciscoSan FranciscoUSA
  3. 3.Department of Global Public Health and Infectious DiseaseSchool of Medicine, University of California, San DiegoSan DiegoUSA
  4. 4.Division of HIV, Infectious Disease, and Global Medicine, Department of MedicineUniversity of California, San FranciscoSan FranciscoUSA
  5. 5.Bio-Rad LaboratoriesRedmondUSA
  6. 6.Blood Systems Research InstituteSan FranciscoUSA
  7. 7.Department of Laboratory MedicineUniversity of California, San FranciscoSan FranciscoUSA
  8. 8.Epidemiology, Biostatistics and Preventive Medicine, Department of Internal MedicineUniversity of New Mexico Health Sciences CenterAlbuquerqueUSA

Personalised recommendations